New agent to treat elevated phosphate levels: magnesium carbonate/calcium carbonate tablets
Caitlin Meyer1, Karen Cameron, Marisa Battistella
1University of Waterloo, Waterloo, ON.
Abstract:
In summary, Binaphos CM, a magnesium carbonate/calcium carbonate combination phosphate binder, is marketed for treating elevated phosphate levels in dialysis patients. Although studies using magnesium/calcium carbonate as a phosphate binder are short term with small numbers of patients, this phosphate binder has shown some promising results and may provide clinicians with an alternative for phosphate binding. Using a combination phosphate binder may reduce pill burden and encourage patient compliance. In addition to calcium and phosphate, it is imperative to diligently monitor magnesium levels in patients started on this medication, as magnesium levels may increase with longer duration of use. Additional randomized controlled trials are necessary to evaluate long-term efficacy and safety of this combination phosphate binder.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily regulated...
Introduction to Electrolytes
Role of Sodium
One...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Chronic Kidney Disease III: Interprofessional Care


